Young Nursing Student’s Knowledge and Attitudes about Contraceptive Methods

We would like to thank all the nursing students who voluntarily participated in this studyPurpose: Adolescence is considered a period in which individuals are particularly at risk of negative consequences related to sexual health. Increased knowledge levels have traditionally been used as an indicator of the effectiveness of educational programs, but attitudes are not addressed and are a key element for the success of such programs. The aim of this study is to determine the level of knowledge and attitudes toward the use of contraceptive methods among nursing students. A multicenter cross-sectional study was carried out. In total, 2914 university students (aged 18–25 years) enrolled in the study. Participants completed two validated scales to measure knowledge level and attitudes toward contraceptive use. Nursing degree students who received training about contraceptives obtained a success rate of over 70%, compared to 15.3% among students who had not received such training (p < 0.001). The mean attitude score was 43.45 points (10–50), but there were no significant differences in terms of student training (p = 0.435), although they were significantly higher among students who used contraceptives at first or last sexual intercourse (p < 0.001). There was a significant weak correlation between the level of knowledge and attitudes toward the use of contraceptives. An adequate level of knowledge about sexuality and contraceptive methods does not correspond to positive attitudes toward their use, although having an excellent attitude toward contraceptive use is related to their use during youth and adolescence

Removal of pharmaceutical compounds commonly-found in wastewater through a hybrid biological and adsorption process

[EN] Nowadays, alternative options to conventional wastewater treatment should be studied due to rising concerns emerged by the presence of pharmaceuticals compounds (PhCs) in the aquatic environment. In this work, a combined system including biological treatment by activated sludge plus adsorption with activated carbon is proposed to remove three selected drugs (acetaminophen (ACT), caffeine (CAF) and ibuprofen (IBU)) in a concentration of 2 mg L-1 of each one. For it three sequencing batch reactors (SBR) were operated. SBR-B treated a synthetic wastewater (SWW) without target drugs and SBR-PhC and SBR-PhC + AC operated with SWW doped with the three drugs, adding into SBR-PhC + AC 1.5 g L-1 of a mesoporous granular activated carbon. Results showed that the hybrid system SBR-activated carbon produced an effluent free of PhCs, which in addition had higher quality than that achieved in a conventional activated sludge treatment in terms of lower COD, turbidity and SMP concentrations. On the other hand, five possible routes of removal for target drugs during the biological treatment were studied. Hydrolysis, oxidation and volatilization pathways were negligible after 6 h of reaction time. Adsorption mute only was significant for ACT, which was adsorbed completely after 5 h of reaction, while only 1.9% of CAF and 5.6% of IBU were adsorbed. IBU was the least biodegradable compound.This work was supported by Spanish grants AICO/2018/292 of the Generalitat Valenciana.Ferrer-Polonio, E.; Fernández-Navarro, J.; Iborra-Clar, MI.; Alcaina-Miranda, MI.; Mendoza Roca, JA. (2020). Removal of pharmaceutical compounds commonly-found in wastewater through a hybrid biological and adsorption process. Journal of Environmental Management. 263:1-8. https://doi.org/10.1016/j.jenvman.2020.110368S18263Al-Khazrajy, O. S. A., & Boxall, A. B. A. (2016). Impacts of compound properties and sediment characteristics on the sorption behaviour of pharmaceuticals in aquatic systems. Journal of Hazardous Materials, 317, 198-209. doi:10.1016/j.jhazmat.2016.05.065Alygizakis, N. A., Gago-Ferrero, P., Borova, V. L., Pavlidou, A., Hatzianestis, I., & Thomaidis, N. S. (2016). Occurrence and spatial distribution of 158 pharmaceuticals, drugs of abuse and related metabolites in offshore seawater. Science of The Total Environment, 541, 1097-1105. doi:10.1016/j.scitotenv.2015.09.145Azimi, S. C., Shirini, F., & Pendashteh, A. (2019). Evaluation of COD and turbidity removal from woodchips wastewater using biologically sequenced batch reactor. Process Safety and Environmental Protection, 128, 211-227. doi:10.1016/j.psep.2019.05.043Boxall, A. B. A. (2004). The environmental side effects of medication. EMBO reports, 5(12), 1110-1116. doi:10.1038/sj.embor.7400307Carballa, M., Omil, F., & Lema, J. M. (2005). Removal of cosmetic ingredients and pharmaceuticals in sewage primary treatment. Water Research, 39(19), 4790-4796. doi:10.1016/j.watres.2005.09.018Couto, C. F., Lange, L. C., & Amaral, M. C. S. (2019). Occurrence, fate and removal of pharmaceutically active compounds (PhACs) in water and wastewater treatment plants—A review. Journal of Water Process Engineering, 32, 100927. doi:10.1016/j.jwpe.2019.100927Desbiolles, F., Malleret, L., Tiliacos, C., Wong-Wah-Chung, P., & Laffont-Schwob, I. (2018). Occurrence and ecotoxicological assessment of pharmaceuticals: Is there a risk for the Mediterranean aquatic environment? Science of The Total Environment, 639, 1334-1348. doi:10.1016/j.scitotenv.2018.04.351Dong, X., Zhou, W., & He, S. (2013). Removal of anaerobic soluble microbial products in a biological activated carbon reactor. Journal of Environmental Sciences, 25(9), 1745-1753. doi:10.1016/s1001-0742(12)60224-1Fan, H., Li, J., Zhang, L., & Feng, L. (2014). Contribution of sludge adsorption and biodegradation to the removal of five pharmaceuticals in a submerged membrane bioreactor. Biochemical Engineering Journal, 88, 101-107. doi:10.1016/j.bej.2014.04.008Frølund, B., Palmgren, R., Keiding, K., & Nielsen, P. H. (1996). Extraction of extracellular polymers from activated sludge using a cation exchange resin. Water Research, 30(8), 1749-1758. doi:10.1016/0043-1354(95)00323-1GilPavas, E., Dobrosz-Gómez, I., & Gómez-García, M.-Á. (2019). Optimization and toxicity assessment of a combined electrocoagulation, H2O2/Fe2+/UV and activated carbon adsorption for textile wastewater treatment. Science of The Total Environment, 651, 551-560. doi:10.1016/j.scitotenv.2018.09.125Goel, R., Mino, T., Satoh, H., & Matsuo, T. (1998). Enzyme activities under anaerobic and aerobic conditions in activated sludge sequencing batch reactor. Water Research, 32(7), 2081-2088. doi:10.1016/s0043-1354(97)00425-9Greenham, R. T., Miller, K. Y., & Tong, A. (2019). Removal efficiencies of top-used pharmaceuticals at sewage treatment plants with various technologies. Journal of Environmental Chemical Engineering, 7(5), 103294. doi:10.1016/j.jece.2019.103294Hampel, M., Alonso, E., Aparicio, I., Bron, J. E., Santos, J. L., Taggart, J. B., & Leaver, M. J. (2010). Potential physiological effects of pharmaceutical compounds in Atlantic salmon (Salmo salar) implied by transcriptomic analysis. Environmental Science and Pollution Research, 17(4), 917-933. doi:10.1007/s11356-009-0282-6Krishnan, V., Ahmad, D., & Jeru, J. B. (2008). Influence of COD:N:P ratio on dark greywater treatment using a sequencing batch reactor. Journal of Chemical Technology & Biotechnology, 83(5), 756-762. doi:10.1002/jctb.1842Li, B., & Zhang, T. (2010). Biodegradation and Adsorption of Antibiotics in the Activated Sludge Process. Environmental Science & Technology, 44(9), 3468-3473. doi:10.1021/es903490hLin, A. Y.-C., Yu, T.-H., & Lateef, S. K. (2009). Removal of pharmaceuticals in secondary wastewater treatment processes in Taiwan. Journal of Hazardous Materials, 167(1-3), 1163-1169. doi:10.1016/j.jhazmat.2009.01.108Mezzelani, M., Gorbi, S., & Regoli, F. (2018). Pharmaceuticals in the aquatic environments: Evidence of emerged threat and future challenges for marine organisms. Marine Environmental Research, 140, 41-60. doi:10.1016/j.marenvres.2018.05.001Min, X., Li, W., Wei, Z., Spinney, R., Dionysiou, D. D., Seo, Y., … Xiao, R. (2018). Sorption and biodegradation of pharmaceuticals in aerobic activated sludge system: A combined experimental and theoretical mechanistic study. Chemical Engineering Journal, 342, 211-219. doi:10.1016/j.cej.2018.01.012Molina-Muñoz, M., Poyatos, J. M., Rodelas, B., Pozo, C., Manzanera, M., Hontoria, E., & Gonzalez-Lopez, J. (2010). Microbial enzymatic activities in a pilot-scale MBR experimental plant under different working conditions. Bioresource Technology, 101(2), 696-704. doi:10.1016/j.biortech.2009.08.071Namkung, E., & Rittmann, B. E. (1986). Soluble microbial products (SMP) formation kinetics by biofilms. Water Research, 20(6), 795-806. doi:10.1016/0043-1354(86)90106-5Palli, L., Spina, F., Varese, G. C., Vincenzi, M., Aragno, M., Arcangeli, G., … Gori, R. (2019). Occurrence of selected pharmaceuticals in wastewater treatment plants of Tuscany: An effect-based approach to evaluate the potential environmental impact. International Journal of Hygiene and Environmental Health, 222(4), 717-725. doi:10.1016/j.ijheh.2019.05.006Pan, M., & Chu, L. M. (2017). Transfer of antibiotics from wastewater or animal manure to soil and edible crops. Environmental Pollution, 231, 829-836. doi:10.1016/j.envpol.2017.08.051Patrolecco, L., Ademollo, N., Grenni, P., Tolomei, A., Barra Caracciolo, A., & Capri, S. (2013). Simultaneous determination of human pharmaceuticals in water samples by solid phase extraction and HPLC with UV-fluorescence detection. Microchemical Journal, 107, 165-171. doi:10.1016/j.microc.2012.05.035Peng, J., Wang, X., Yin, F., & Xu, G. (2019). Characterizing the removal routes of seven pharmaceuticals in the activated sludge process. Science of The Total Environment, 650, 2437-2445. doi:10.1016/j.scitotenv.2018.10.004Hamon, P., Villain, M., & Marrot, B. (2014). Determination of sorption properties of micropollutants: What is the most suitable activated sludge inhibition technique to preserve the biomass structure? Chemical Engineering Journal, 242, 260-268. doi:10.1016/j.cej.2013.07.117Pomiès, M., Choubert, J.-M., Wisniewski, C., & Coquery, M. (2013). Modelling of micropollutant removal in biological wastewater treatments: A review. Science of The Total Environment, 443, 733-748. doi:10.1016/j.scitotenv.2012.11.037Rabiet, M., Togola, A., Brissaud, F., Seidel, J.-L., Budzinski, H., & Elbaz-Poulichet, F. (2006). Consequences of Treated Water Recycling as Regards Pharmaceuticals and Drugs in Surface and Ground Waters of a Medium-sized Mediterranean Catchment. Environmental Science & Technology, 40(17), 5282-5288. doi:10.1021/es060528pSantos, J. L., Aparicio, I., Callejón, M., & Alonso, E. (2009). Occurrence of pharmaceutically active compounds during 1-year period in wastewaters from four wastewater treatment plants in Seville (Spain). Journal of Hazardous Materials, 164(2-3), 1509-1516. doi:10.1016/j.jhazmat.2008.09.073Thiebault, T., Chassiot, L., Fougère, L., Destandau, E., Simonneau, A., Van Beek, P., … Chapron, E. (2017). Record of pharmaceutical products in river sediments: A powerful tool to assess the environmental impact of urban management? Anthropocene, 18, 47-56. doi:10.1016/j.ancene.2017.05.006Vona, A., di Martino, F., Garcia-Ivars, J., Picó, Y., Mendoza-Roca, J.-A., & Iborra-Clar, M.-I. (2015). Comparison of different removal techniques for selected pharmaceuticals. Journal of Water Process Engineering, 5, 48-57. doi:10.1016/j.jwpe.2014.12.011Wattanasin, P., Saetear, P., Wilairat, P., Nacapricha, D., & Teerasong, S. (2015). Zone fluidics for measurement of octanol–water partition coefficient of drugs. Analytica Chimica Acta, 860, 1-7. doi:10.1016/j.aca.2014.08.025Zhou, S., Di Paolo, C., Wu, X., Shao, Y., Seiler, T.-B., & Hollert, H. (2019). Optimization of screening-level risk assessment and priority selection of emerging pollutants – The case of pharmaceuticals in European surface waters. Environment International, 128, 1-10. doi:10.1016/j.envint.2019.04.034Zuriaga-Agustí, E., Bes-Piá, A., Mendoza-Roca, J. A., & Alonso-Molina, J. L. (2013). Influence of extraction methods on proteins and carbohydrates analysis from MBR activated sludge flocs in view of improving EPS determination. Separation and Purification Technology, 112, 1-10. doi:10.1016/j.seppur.2013.03.04

Correction : Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J. Clin. Med. 2021, 10, 2885

The authors wish to make the following corrections to this paper [...]

Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain : Large-Scale Epidemiological Study

(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD-Crohn's disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)-during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31-56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery

Accurate and timely diagnosis of Eosinophilic Esophagitis improves over time in Europe. An analysis of the EoE CONNECT Registry

BACKGROUND: Poor adherence to clinical practice guidelines for eosinophilic esophagitis (EoE) has been described and the diagnostic delay of the disease continues to be unacceptable in many settings. OBJECTIVE: To analyze the impact of improved knowledge provided by the successive international clinical practice guidelines on reducing diagnostic delay and improving the diagnostic process for European patients with EoE. METHODS: Cross‐sectional analysis of the EoE CONNECT registry based on clinical practice. Time periods defined by the publication dates of four major sets of guidelines over 10 years were considered. Patients were grouped per time period according to date of symptom onset. RESULTS: Data from 1,132 patients was analyzed and median (IQR) diagnostic delay in the whole series was 2.1 (0.7‐6.2) years. This gradually decreased over time with subsequent release of new guidelines (p < 0.001), from 12.7 years up to 2007 to 0.7 years after 2017. The proportion of patients with stricturing of mixed phenotypes at the point of EoE diagnosis also decreased over time (41.3% vs. 16%; p < 0.001), as did EREFS scores. The fibrotic sub‐score decreased from a median (IQR) of 2 (1‐2) to 0 (0‐1) when patients whose symptoms started up to 2007 and after 2017 were compared (p < 0.001). In parallel, symptoms measured with the Dysphagia Symptoms Score reduced significantly when patients with symptoms starting before 2007 and after 2012 were compared. A reduction in the number of endoscopies patients underwent before the one that achieved an EoE diagnosis, and the use of allergy testing as part of the diagnostic workout of EoE, also reduced significantly over time (p = 0.010 and p < 0.001, respectively). CONCLUSION: The diagnostic work‐up of EoE patients improved substantially over time at the European sites contributing to EoE CONNECT, with a dramatic reduction in diagnostic delay

EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis: rationale, design, and study protocol of a large-scale epidemiological study in Europe

Background: The growing prevalence of eosinophilic esophagitis (EoE) represents a considerable burden to patients and health care systems. Optimizing cost-effective management and identifying mechanisms for disease onset and progression are required. However, the paucity of large patient cohorts and heterogeneity of practice hinder the defining of optimal management of EoE. Methods: EoE CONNECT is an ongoing, prospective registry study initiated in 2016 and currently managed by EUREOS, the European Consortium for Eosinophilic Diseases of the Gastrointestinal Tract. Patients are managed and treated by their responsible specialists independently. Data recorded using a web-based system include demographic and clinical variables; patient allergies; environmental, intrapartum, and early life exposures; and family background. Symptoms are structurally assessed at every visit; endoscopic features and histological findings are recorded for each examination. Prospective treatment data are registered sequentially, with new sequences created each time a different treatment (active principle, formulation, or dose) is administered to a patient. EoE CONNECT database is actively monitored to ensure the highest data accuracy and the highest scientific and ethical standards. Results: EoE CONNECT is currently being conducted at 39 centers in Europe and enrolls patients of all ages with EoE. In its aim to increase knowledge, to date EoE CONNECT has provided evidence on the effectiveness of first- and second-line therapies for EoE in clinical practice, the ability of proton pump inhibitors to induce disease remission, and factors associated with improved response. Drug effects to reverse fibrous remodeling and endoscopic features of fibrosis in EoE have also been assessed. Conclusion: This prospective registry study will provide important information on the epidemiological and clinical aspects of EoE and evidence as to the real-world and long-term effectiveness and safety of therapy. These data will potentially be a vital benchmark for planning future EoE health care services in Europe

RNAi-Based Functional Genomics Identifies New Virulence Determinants in Mucormycosis

Mucorales are an emerging group of human pathogens that are responsible for the lethal disease mucormycosis. Unfortunately, functional studies on the genetic factors behind the virulence of these organisms are hampered by their limited genetic tractability, since they are reluctant to classical genetic tools like transposable elements or gene mapping. Here, we describe an RNAi-based functional genomic platform that allows the identification of new virulence factors through a forward genetic approach firstly described in Mucorales. This platform contains a whole-genome collection of Mucor circinelloides silenced transformants that presented a broad assortment of phenotypes related to the main physiological processes in fungi, including virulence, hyphae morphology, mycelial and yeast growth, carotenogenesis and asexual sporulation. Selection of transformants with reduced virulence allowed the identification of mcplD, which encodes a Phospholipase D, and mcmyo5, encoding a probably essential cargo transporter of the Myosin V family, as required for a fully virulent phenotype of M. circinelloides. Knock-out mutants for those genes showed reduced virulence in both Galleria mellonella and Mus musculus models, probably due to a delayed germination and polarized growth within macrophages. This study provides a robust approach to study virulence in Mucorales and as a proof of concept identified new virulence determinants in M. circinelloides that could represent promising targets for future antifungal therapies

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

Guía Mexicana para el Diagnóstico y el Tratamiento de la Urticaria

La urticaria es una enfermedad que padece una quinta parte de la población en algún momento de su vida. Las guías inter- nacionales recientes han propuesto unos cambios de fondo en su diagnóstico y tratamiento, por lo que había la necesidad de crear una guía nacional y multidisciplinaria, con base amplia en los gremios de especialistas y médicos de primer contacto en México. ABSTRACT Urticaria is a disease that a fifth of the population shall suffer once in a lifetime. Recent clinical guidelines have proposed some fundamental changes in the diagnosis and treatment of urticaria, making the development of a national, multidisciplinary guideline, with wide acceptability among different professional groups –both specialists and primary health care workers–, necessary in Mexico